Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Study of ONC201 in Neuroendocrine Tumors

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
1. Subjects must have a unresectable, recurrent, locally advanced, refractory, or metastatic neuroendocrine tumor including pheochromocytoma-paraganglioma (PC-PG), DSRCT, Ewing Sarcoma or PNET, or any neuroendocrine tumor with a catecholamine or dopamine biomarker or autocrine or paracrine dependence on dopamine including cholangiocarcinoma and adrenal cortical carcinoma (ACC).~2. There is no limit on number of prior therapies.~3. Age ≥14 years.~4. Subjects must have normal organ and marrow function as defined below. Studies should be done within 3 weeks prior to enrollment~   * Hemoglobin ≥ 10.0 g/dl~  * Leukocytes ≥ 1500/mcL~  * Absolute neutrophil count ≥ 1,000/mcL~  * Platelet count ≥ 75000/mcL~  * Total bilirubin within 1.5 x normal institutional limits~  * AST (SGOT) ≤ 5 X institutional upper limit of normal~  * ALT (SGPT) ≤ 5 X institutional upper limit of normal~  * Serum Creatinine \<3.0mg/dL~     * 5 1 lesion detectable on CT, MRI, 18FDG PET-CT~6 Subjects must have the ability to understand and the willingness to sign a written informed consent document.~7: Karnofsky or if \<16 years old Lansky Play Performance status ≥ 60%

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A: Metastatic PC-PG (Type: EXPERIMENTAL): 625mg ONC201 will be given once weekly
- Arm B: Other NETs (Type: EXPERIMENTAL): 625mg ONC201 will be given once weekly
- Arm C: PC-PG + other NETs (Type: EXPERIMENTAL): 625mg ONC201 will be given on day 1 and day 2 of each week

Based on this trial design, predict the completion outcome and termination type (if applicable).